{
    "id": 24021,
    "cites": 57,
    "cited_by": 0,
    "reference": [
        "Anderson, T. W., and C. Hsiao. 1981. Estimation of dynamic models with error components. Journal of the American Statistical Association 76: 598-606.",
        "Asbury, C.H., 1991, The Orphan Drug Act. The first 7-years. The Journal of the American Medical Association, 265, 893-897.",
        "Baltagi, B. H., and S. Khanti-Akom. 1990. On efficient estimation with panel data: An empirical comparison of instrumental variables. Journal of Applied Econometrics 5: 401-406.",
        "Brau, J., and Fawcett, S., 2006, Initial Public Offerings: An Analysis of Theory and Practice. The Journal of Finance, LXI, 399-436.",
        "Carter, R., and Manaster, S., 1990, Initial public offerings and underwriter reputation. The Journal of Finance, 45, 1045-1067.",
        "Certo, S.T., Holmes, M.R.Jr, and Holcomb, T.R., 2007, The influence of people on the performance of IPO firms. Business Horizons, 50, 271-276.",
        "Chang S.J., 2004, Venture capital financing, strategic alliances, and the initial public offerings of Internet startups. Journal of Business Venturing, 19, 721\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c41.",
        "Chemmanur, T., and Fulghieri, P., 1994, Investment bank reputation, information production, and financial intermediation. Journal of Finance, 49, 57\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c79.",
        "Chok, J., and Qian, J., 2013, Do executives\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 backgrounds matter to IPO investors? Evidence from the life science industry. PlosOne, 8, e60911.",
        "Conti, A., Thursby, J. and Thursby, M.C., 2013, Patents as signals for start-up financing. NBER working paper, w19191.",
        "C\u00c3\u0083\u00c2\u00b4t\u00c3\u0083\u00c2\u00a9, A., 2012, What Is Wrong with Orphan Drug Policies? Value in Health, 15, 1185-1191.",
        "Fernandez, J-M., Stein, R.M., and Lo, A.W., 2012, Commercialization biomedical research through securitization techniques. Nature Biotechnology, 30, 964-975.",
        "Garden, H., Gorry, P., and Paris, V., 2017, Health Innovation for Rare Diseases. OECD (eds), Science, Technology and Innovation Outlook 2016, Paris (France), OECD Publishing.",
        "Gompers P.A., 1995, Optimal investment, monitoring, and the staging of venture capital. Journal of Finance, 50, 1461\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c90.",
        "Guo, R-J., Lev, B., and Zhou, N., 2005, The valuation of Biotech IPOs. Journal of Accounting, Auditing and Finance, 20, 423-459.",
        "Hay, M., Thomas, D.W., Craighead, J.L., Economides, C., and Rosenthal, J., 2014, Clinical development success rates for investigational drugs. Nature Biotechnology, 32, 40-51.",
        "Heeley, M.B., Matusik, S.F., and Jain, N., 2007, Innovation, appropriability and the underpricing of Initial Public Offerings. Academy of Management Journal, 50, 209-225.",
        "Higgins, M.C., and Gulati, R., 2003, Getting off to a good start: the effects of upper echelon affiliations on underwriter prestige. Organization Science, 14, 244\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c263.",
        "Higgins, M.J., Stephan P.E., Thursby, J.G., 2011, Conveying quality and value in emerging industries: Start scientists and the role of signal in biotechnology. Research Policy, 40, 605-617.",
        "GORRY-USECHE NBER PPMf2017 Hoenen, S., Kolympris, C., Schoenmakers, W., and Kalaitzandonakes, N., 2014, The diminishing signaling value of patents between early rounds of venture capital financing. Research Policy, 43, 956-989.",
        "Hoenig, D., and Henkel, J., 2015, Quality signals? The role of patents, alliances, and team experience in venture capital financing. Research Policy, 44, 1049-1064.",
        "Hsu, D., Ziedonis, R.H., 2008, Patents as Quality Signals for Entrepreneurial Ventures, Academy of Management Best Papers Proceedings.",
        "Hughes, J.P., Rees, S., Kalindjian, S.B., Philpott, K.L., 2011, Principles of early drug discovery, British Journal of Pharmacology, 162, 1239\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1249.",
        "Jaffe, A., and Lerner, J., 2004, Innovation and Its Discontents: How Our Broken Patent System is Endangering Innovation and Progress, and What to Do About It. Princeton, NJ. Princeton University Press.",
        "Kesselheim, A.S., Myers, J.A., and Avorn, J., 2011, Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer. The Journal of the American Medical Association, 305, 2320-2326.",
        "Krinsky, I., and Rotenberg, W., 1989, The valuation of initial public offerings. Contemporary Accounting Research, 5, 501\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c515.",
        "Lazonick, W., and Tulum, O., 2011, US biopharmaceutical finance and the sustainability of the biotech business model. Research Policy, 40, 1170-1187.",
        "Leland H.E., and Pyle, D.H., 1977, Informational asymmetries, financial structure, and financial intermediation. Journal of Finance, 32, 371-387.",
        "Lemley, M.A., 2001, Rational Ignorance at the Patent Office. Northwestern University Law Review, 95, 1495-1532.",
        "Lerner, J., 1994, Venture capitalists and the decision to go public. Journal of Financial Economics, 35, 293\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 316.",
        "Levin, R. C., Klevorick, A.K., Nelson, R.R. and Winter, S.G., 1987, Appropriating the Returns from Industrial Research and Development. Brookings Papers on Economic Activity, 3, 783-832.",
        "LiPuma, J., 2012, Internationalization and the IPO performance of new ventures. Journal of Business Research, 65, 914-921.",
        "Long C., 2002, Patent signals. The University of Chicago Law Review, 69, 625-679.",
        "Loughran, T., and Ritter, J., 2004, Why has IPO underpricing changed over time? Financial Management, 33, 5-37.",
        "Mann, R., 2005, Do patents facilitate financing in the software Industry? Texas Law Review, 83, 961-1030.",
        "Mansfield, E., Schwartz, M., and Wagner, S., 1981, Imitation costs and patents: an empirical study. Economic Journal, 91, 907-918.",
        "Mayston, D., 2009, The Determinants of Cumulative Endogeneity Bias in Multivariate. Analysis. Journal of Multivariate Analysis, 100, 1120-1136.",
        "Megginson, W.L., and Weiss, K.A., 1991, Venture capitalist certification in initial public offerings. Journal of Finance, 46, 879\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c903.",
        "Moors, E.H.M., and Faber, J., 2007, Orphan drugs: Unmet societal need for non-profitable privately supplied new products. Research Policy, 36, 336-354.",
        "GORRY-USECHE NBER PPMf2017 Muller P., and P\u00c3\u0083\u00c2\u00a9nin, J., 2006, Why do firms disclose knowledge and how does it matter? Journal of Evolutionary Economics, 16, 85-108.",
        "Noel, M.D., and Schankermann, M.A., 2006, Strategic Patenting and Software Innovation. The Journal of Industrial Organization, 61,481-520.",
        "Orsenigo, L, and Sterzi, V., 2010, Comparative study if the use of patents in different industries. KITeS Working Paper, n33.",
        "Oslon, K., 2004, Firm Characteristics and the Speed of FDA Approval. Journal of Economics and Management, 6, 377-401.",
        "Paul, S.M., Mytelka, D.S., Dunwiddie, C.T., Persinger C.C., Munos, B.H., Lindborg, S.R. and Schach, AL., 2010, How to improve R&D productivity: the pharmaceutical industry\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s grand challenge. Nature Reviews Drug Discovery, 9, 203-214.",
        "Pisano, G.P., 2006, Can science be a business? Lessons from biotech. Harvard Business Review, 84, 114\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 124.",
        "Rzakhanov, Z., 2008, Regulatory policy, value of knowledge assets and innovation strategy: The case of the Orphan Drug Act. Research Policy, 37, 673\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c689.",
        "Rinaldi, A., 2005, Adopting an orphan. EMBO Report, 6, 507\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 510.",
        "Ritter, J.R., 1984, Signaling and the valuation of unseasoned new issues: A comment. Journal of Finance, 39, 1231-1237.",
        "Ritter, J.R., and Welch I., 2002, A Review of IPO Activity, Pricing, and Allocations. Journal of Finance, 57, 1795\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1828.",
        "Seoane-Vazquez, E., Rodriguez-Monguio, R., Szeinbach, S.L., and Visaria, J., 2008, Incentives for orphan drug research and development in the United States. Orphanet Journal of Rare Disease, 3, 33-39.",
        "Spence, M., 1973, Job Market Signaling. Quarterly Journal of Economics, 87, 355-374.",
        "Stuart, T., Hoang, H., and Hybels, R.G., 1999, Interorganizational endorsement and the performance of entrepreneurial ventures. Administrative Science Quarterly, 44, 315\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c349.",
        "Trajtenberg, M., 1990, A penny for your quotes: patent citations and the value of innovations. The Rand Journal of Economics, 21, 172-187.",
        "Useche, D., 2014, Are patents signals for the IPO market? An EU-US comparison for the software industry.",
        "Wilbon, A.D., 1999, An empirical investigation of technology strategy in computer software initial public offering firms. Journal of Engineering and Technology Management, 16, 147\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c169.",
        "Windmeijer, F. 2005. A finite sample correction for the variance of linear efficient two-step GMM estimators. Journal of Econometrics 126: 25-51.",
        "Yin, W., 2008, Market incentives and pharmaceutical innovation. Journal of Health Economics 27 : 10601077. GORRY-USECHE NBER PPMf2017"
    ]
}